Barrier Submits “Complete Response” For The Drug Formerly Known As Zimycan
This article was originally published in The Pink Sheet Daily
Executive Summary
Submission of supplemental information on the antifungal puts the review deadline in mid-February, the firm says.
You may also be interested in...
Novartis Consumer Health Sales Force To Detail Barrier’s Vusion Ointment
Barrier also moving forward with Phase IV commitments, exec tells “The Pink Sheet” DAILY.
Novartis Consumer Health Sales Force To Detail Barrier’s Vusion Ointment
Barrier also moving forward with Phase IV commitments, exec tells “The Pink Sheet” DAILY.
Vusion Breaks “Not Approvable” Barrier With Dermatitis NDA
Barrier Therapeutics receives FDA approval for the antifungal ointment after submitting a complete response to a May 2005 “not-approvable” letter.